Meanwhile, in mice that were prone to develop neurofibromas, the cancer drug
Gleevec — an inhibitor of c-kit — reduced the metabolic activity and size of the tumors.
Because Gleevec is already prescribed for chronic myelogenous leukemia and other cancers, the researchers were able to secure fast regulatory approval for a phase 2 clinical trial of the drug in children and adults with neurofibromatosis type 1.